Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 449-462 , December 2000

The blood-brain barrier and oncology: new insights into function and modulation

  • J. Bart

      Affiliations

    • Department of Pulmonary Diseases, University Hospital Groningen, The Netherlands
    • Department of Medical Oncology, University Hospital Groningen, The Netherlands
    • ,
  • H.J.M. Groen

      Affiliations

    • Department of Pulmonary Diseases, University Hospital Groningen, The Netherlands
    • ,
  • N.H. Hendrikse

      Affiliations

    • PET Center, University Hospital Groningen, The Netherlands
    • ,
  • W.T.A. van der Graaf

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, The Netherlands
    • ,
  • W. Vaalburg

      Affiliations

    • PET Center, University Hospital Groningen, The Netherlands
    • ,
  • E.G.E. de Vries

      Affiliations

    • Department of Medical Oncology, University Hospital Groningen, The Netherlands

References 

    REFERENCES
  1. Nugent JL, Bunn PA, Matthews MJ. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 1979;44:1885–1893
  2. Scheffer GL, Wijngaard PL, Flens MJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1995;1:578–582
  3. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265–269
  4. Cole SP, Bhardwaj G, Gerlach JH. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–1654
  5. Sugawara I, Kataoka I, Morishita Y. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988;48:1926–1929
  6. Hendrikse NH, Schinkel AH, de Vries EGE. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol. 1998;124:1413–1418
  7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84:7735–7738
  8. Cordon-Cardo C, O’Brien JP, Casals D. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695–698
  9. Stewart DJ, Lu K, Benjamin RS. Concentration of vinblastine in human intracerebral tumor and other tissues. J Neurooncol. 1983;1:139–144
  10. Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V. Human central nervous system and plasma pharmacology of mitoxantrone. J Neurooncol. 1988;6:75–83
  11. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999;125:481–486
  12. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA. 1982;79:4420–4423
  13. Dean RL, Emerich DF, Hasler BP, Bartus RT. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro-Oncology. 1999;1:268–274
  14. Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?. Neurology. 1997;48:1704–1709
  15. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr 1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96:1698–1705
  16. Straathof CS, van den Bent MJ, Loos WJ, Vecht CJ, Schellens JH. The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. J Neurooncol. 1999;42:117–122
  17. Twelves CJ, Souhami RL, Harper PG. The response of cerebral metastases in small celllung cancer to systemic chemotherapy. Br J Cancer. 1990;61:147–150
  18. Groen HJM, Smit EF, Haaxma-Reiche H, Postmus PE. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer. 1993;29A:1696–1699
  19. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem. 1992;267:20383–20391
  20. Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit. 1998;20:588–590
  21. Jette L, Murphy GF, Leclerc JM, Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol. 1995;50:1701–1709
  22. van Asperen J, Mayer U, van Tellingen O, Beijnen JH. The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci. 1997;86:881–884
  23. Kool M, de Haas M, Scheffer GL. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537–3547
  24. Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999;59:175–182
  25. Huai-Yun H, Secrest DT, Mark KS. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun. 1998;243:816–820
  26. Angeletti RH, Bergwerk AJ, Novikoff PM, Wolkoff AW. Dichotomous development of the organic anion transport protein in liver and choroid plexus. Am J Physiol. 1998;275:C882–C887
  27. Rao VV, Dahlheimer JL, Bardgett ME. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA. 1999;96:3900–3905
  28. Sugiyama Y, Kusuhara H, Suzuki H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J Controlled Release. 1999;62:179–186
  29. Wijnholds J, de Lange EC, Scheffer GL. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest. 2000;105:279–285
  30. Noe B, Hagenbuch B, Stieger B, Meier PJ. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA. 1997;94:10346–10350
  31. Abbott NJ, Revest PA. Control of brain endothelial permeability. Cerebrovasc Brain Metab Rev. 1991;3:39–72
  32. Coomber BL, Stewart PA. Morphometric analysis of CNS microvascular endothelium. Microvasc Res. 1985;30:99–115
  33. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11–28
  34. Stewart PA, Wiley MJ. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail—chick transplantation chimeras. Dev Biol. 1981;84:183–192
  35. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987;325:253–257
  36. Staddon JM, Rubin LL. Cell adhesion, cell junctions and the blood-brain barrier. Curr Opin Neurobiol. 1996;6:622–627
  37. Sobue K, Yamamoto N, Yoneda K. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res. 1999;35:155–164
  38. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol (Lond). 1990;429:47–62
  39. Hirase T, Staddon JM, Saitou M. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci. 1997;110:1603–1613
  40. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol (Berl). 1989;78:561–571
  41. Hirano A, Matsui T. Vascular structures in brain tumors. Hum Pathol. 1975;6:611–621
  42. Stewart DJ, Richard MT, Hugenholtz H. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol. 1984;2:133–139
  43. Stewart DJ, Leavens M, Maor M. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982;42:2474–2479
  44. Stewart DJ, Leavens M, Friedman J. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Res. 1980;40:3163–3166
  45. Kiya K, Uozumi T, Ogasawara H. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol. 1992;29:339–342
  46. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999;10:753–759
  47. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980;23:682–684
  48. Johnson MD, Anderson BD. In vitro models of the blood-brain barrier to polar permeants: comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells. J Pharm Sci. 1999;88:620–625
  49. Jette L, Tetu B, Beliveau R. High levels of P-glycoprotein detected in isolated brain capillaries. Biochim Biophys Acta. 1993;1150:147–154
  50. Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem. 1996;67:1688–1693
  51. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997;100:2430–2436
  52. Clifford SC, Neal DE, Lunec J. High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?. Carcinogenesis. 1996;17:601–604
  53. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38:1277–1287
  54. De Boer AB, De Lange EL, Van der Sandt I, Breimer DD. Transporters and the blood-brain barrier (BBB). Int J Clin Pharmacol Ther. 1998;36:14–15
  55. Schinkel AH, Smit JJ, van Tellingen O. Disruption of the mouse mdr la P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502
  56. Jonker JW, Wagenaar E, van Deemter L. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol. 1999;127:43–50
  57. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdrla (–/–) and mdrla (+/+) mice. Br J Pharmacol. 1999;128:563–568
  58. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152–162
  59. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell. 1986;47:371–380
  60. Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med. 1999;26:283–293
  61. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977–984
  62. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell. 1992;71:23–32
  63. Eytan GD, Kuchel PW. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int Rev Cytol. 1999;190:175–250
  64. Ohnishi T, Tamai I, Sakanaka K. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol. 1995;49:1541–1544
  65. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113
  66. Seetharaman S, Barrand MA, Maskell L, Scheper RJ. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem. 1998;70:1151–1159
  67. Zhu BT. A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol Carcinog. 1999;25:1–13
  68. el Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand). 1999;45:15–23
  69. Britto MR, Wedlund PJ. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab Dispos. 1992;20:446–450
  70. Morse DC, Stein AP, Thomas PE, Lowndes HE. Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain. Toxicol Appl Pharmacol. 1998;152:232–239
  71. Fischer V, Rodriguez-Gascon A, Heitz F. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos. 1998;26:802–811
  72. Lum BL, Fisher GA, Brophy NA. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993;72:3502–3514
  73. Van der Valk P, Van Kalken CK, Ketelaars H. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990;1:56–64
  74. Yang CP, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem. 1989;264:782–788
  75. Thorgeirsson SS, Silverman JA, Gant TW, Marino PA. Multidrug resistance gene family and chemical carcinogens. Pharmacol Ther. 1991;49:283–292
  76. Gosland MP, Gillespie MN, Tsuboi CP. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Cancer Chemother Pharmacol. 1996;37:593–600
  77. Gosland M, Tsuboi C, Hoffman T, Goodin S, Vore M. 17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Cancer Res. 1993;53:5382–5385
  78. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999;288:348–357
  79. Pascaud C, Garrigos M, Orlowski S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J. 1998;333:351–358
  80. Jolliet-Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol. 1999;13:16–26
  81. Seelig A. How does P-glycoprotein recognize its substrates?. Int J Clin Pharmacol Ther. 1998;36:50–54
  82. Ueda K, Yoshida A, Amachi T. Recent progress in P-glycoprotein research. Anticancer Drug Des. 1999;14:115–121
  83. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature. 1992;355:830–833
  84. Abraham EH, Prat AG, Gerweck L. The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci USA. 1993;90:312–316
  85. Zaman GJ, Versantvoort CH, Smit JJ. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993;53:1747–1750
  86. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 1993;53:3221–3225
  87. Regina A, Koman A, Piciotti M. MRP1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem. 1998;71:705–715
  88. Kool M, van der Linden M, de Haas M. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA. 1999;96:6914–6919
  89. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999;1461:347–357
  90. Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res. 1999;16:402–407
  91. Evers R. Zaman GJ, van Deemter L et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest. 1996;97:1211–1218
  92. Evers R, Kool M, van Deemter L. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest. 1998;101:1310–1319
  93. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta. 1999;1461:377–394
  94. Flens MJ, Zaman GJ, van der Valk P. Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996;148:1237–1247
  95. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther. 1998;285:1260–1265
  96. Muller M, Meijer C, Zaman GJ. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA. 1994;91:13033–13037
  97. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer. 1995;72:82–89
  98. Muller M, de Vries EGE, Jansen PLM. Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells. J Hepatol. 1996;24 (Suppl 1):100–108
  99. Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994;269:27807–27810
  100. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J. 1997;327 (Pt 1):305–310
  101. Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999;274:15181–15185
  102. Hooijberg JH, Broxterman HJ, Kool M. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532–2535
  103. Muller, M. Human ATP Binding Cassette transporters. 2000
  104. McAleer MA, Breen MA, White NL, Matthews N. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem. 1999;274:23541–23548
  105. Kusuhara H, Sekine T, Utsunomiya-Tate N. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999;274:13675–13680
  106. Neuwelt EA, Howieson J, Frenkel EP. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery. 1986;19:573–582
  107. Gumerlock MK, Belshe BD, Madsen R, Watts C. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol. 1992;12:33–46
  108. Iwadate Y, Namba H, Saegusa T, Sueyoshi K. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J Neurooncol. 1993;15:185–193
  109. Neuwelt EA, Goldman DL, Dahlborg SA. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol. 1991;9:1580–1590
  110. Miyagami M, Tsubokawa T, Tazoe M, Kagawa Y. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir (Tokyo). 1990;30:582–590
  111. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 1995;705:125–135
  112. Emerich DF, Snodgrass P, Dean R. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer. 1999;80:964–970
  113. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res. 1998;801:259–266
  114. Straub JA, Akiyama A, Parmar P, Musso GF. Limited enzymatic digestion for the determination of the quantities of minor diastereomeric impurities in preparations of RMP-7, a peptide containing a reduced peptide bond. J Chromatogr A. 1994;679:85–91
  115. Elliott PJ, Hayward NJ, Huff MR. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol. 1996;141:214–224
  116. Elliott PJ, Hayward NJ, Dean RL, Blunt DG, Bartus RT. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res. 1996;56:3998–4005
  117. Bartus RT, Elliott PJ, Dean RL. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol. 1996;142:14–28
  118. Riley MG, Kim NN, Watson VE. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine. J Neurooncol. 1998;36:167–178
  119. Ford J, Osborn C, Barton T, Bleehen NM. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer. 1998;34:1807–1811
  120. Whittle IR, Malcolm G, Jodrell DI, Reid M. Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin. Br J Neurosurg. 1999;13:132–137
  121. Lemaire M, Bruelisauer A, Guntz P, Sato H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol. 1996;38:481–486
  122. Walker RW, Brochstein JA. Neurologic complications of immunosuppressive agents. Neurol Clin. 1988;6:261–278
  123. Shah AK. Cyclosporine A neurotoxicity among bone marrow transplant recipients. Clin Neuropharmacol. 1999;22:67–73
  124. Woo M, Przepiorka D, Ippoliti C. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997;20:1095–1098
  125. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246:339–346
  126. Rowinsky EK, Smith L, Wang YM. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998;16:2964–2976
  127. Fenart L, Buee SV, Descamps L. Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm Res. 1998;15:993–1000
  128. Wood L, Palmer M, Hewitt J. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer. 1998;77:627–631
  129. Dantzig AH, Shepard RL, Law KL. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999;290:854–862
  130. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99:552–557
  131. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40 (Suppl):S13–S19
  132. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol. 1999;10:S53–S59
  133. Advani R, Saba Hl, Tallman MS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999;93:787–795
  134. Baer MR, George SL, Dodge RK. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukamia (AML) patients 60 years (CALGB 9720). Blood. 1999;94:383a
  135. Courtois A, Payen L, Vernhet L, de Vries EGE, Guillouzo A, Fardel O. Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells. Cancer Lett. 1999;139:97–104
  136. Depre M, Margolskee DJ, Hsieh JY. Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man. Eur J Clin Pharmacol. 1992;43:427–430
  137. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K. Biricodar (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999;80:1190–1196
  138. Chuman Y, Chen ZS, Seto K. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett. 1998;129:69–76
  139. Grech KV, Davey RA, Davey MW. The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells. Biochem Pharmacol. 1998;55:1283–1289
  140. Vanhoefer U, Cao S, Minderman H. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996;2:1961–1968
  141. Bailey HH, Mulcahy RT, Tutsch KD. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol. 1994;12:194–205
  142. O’Dwyer PJ, Hamilton TC, LaCreta FP. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 1996;14:249–256
  143. Aszalos A, Thompson K, Yin JJ, Ross DD. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res. 1999;19:1053–1064
  144. Hipfner DR, Mao Q, Qiu W. Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein. J Biol Chem. 1999;274:15420–15426
  145. Noonan KE, Beck C, Holzmayer TA. Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA. 1990;87:7160–7164
  146. Bailly JD, Muller C, Jaffrezou JP. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 1995;9:799–807
  147. Wang Q, Yang H, Miller DW, Elmquist WF. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun. 1995;211:719–726
  148. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med. 1994;35:510–515
  149. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun. 1995;16:253–257
  150. Hendrikse NH, Franssen EJF, van der Graaf WTA. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77:353–358
  151. Hendrikse NH, de Vries EGE, Eriks-Fluks L. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 1999;59:2411–2416
  152. Mima T, Toyonaga S, Mori K, Taniguchi T, Ogawa Y. Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation. Neurol Res. 1999;21:209–215
  153. Reinhold HS, Calvo W, Hopewell JW, van der Berg AP. Development of blood vessel-related radiation damage in the fimbria of the central nervous system. Int J Radiat Oncol Biol Phys. 1990;18:37–42
  154. Rubin P, Gash DM, Hansen JT, Nelson DF, Williams JP. Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol. 1994;31:51–60
  155. Fike JR, Gobbel GT, Mesiwala AH. Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain. J Neurooncol. 1998;37:199–215
  156. Fetell MR, Grossman SA, Fisher JD. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol. 1997;15:3121–3128
  157. Madajewicz S, Chowhan N, Tfayli A. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer. 2000;88:2350–2356
  158. Groothuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol. 1997;3:387–400
  159. Lee CG, Gottesman MM, Cardarelli CO. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998;37:3594–3601
  160. Gallo JM. Delivery of anti-HIV nucleosides to the central nervous system. Advanced Drug Delivery Reviews. 1994;14:199–209
  161. Gallo JM. The ins and outs of antiviral drug transport in the brain. J Neurovirol. 1997;3:385–386
  162. Dianzani F, Antonelli G, Turriziani O. Resistance of HIV to antiretroviral agents. Basic concepts. J Biol Regul Homeost Agents. 1998;12:19–22
  163. Patchell RA. Neurological complications of organ transplantation. Ann Neurol. 1994;36:688–703
  164. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology. 1995;45:1962–1964
  165. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725–1738
  166. Schwartz RB, Bravo SM, Klufas RA. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol. 1995;165:627–631
  167. Welge-Lussen UC, Gerhartz HH. Late onset of neurotoxicity with cyclosporin. Lancet. 1994;343:293
  168. Marques-Santos LF, Bernardo RR, de Paula EF, Rumjanek VM. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacol Toxicol. 1999;84:125–129
  169. Burgio DE, Gosland MP, McNamara A. Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. J Pharmacol Exp Ther. 1998;287:911–917
  170. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357–361
  171. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517–2524
  172. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40 (Suppl):S3–S8
  173. Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther. 1999;289:1084–1089
  174. Hauser IA, Koziolek M, Hopfer U, Thevenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int. 1998;54:1139–1149
  175. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos. 1999;27:827–834
  176. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999;258:513–518
  177. Horton JK, Thimmaiah KN, Altenberg GA. Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P- glycoprotein. Mol Pharmacol. 1997;52:948–957
  178. Gutmann H, Torok M, Fricker G, Huwyler J, Beglinger C, Drewe J. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug Metab Dispos. 1999;27:937–941
  179. Chen ZS, Kawabe T, Ono M. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999;56:1219–1228
  180. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998;20:931–940

PII: S0305-7372(00)90194-4

doi: 10.1053/ctrv.2000.0194

Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 449-462 , December 2000

Article Tools